Well given the design of the trial - one arm, open label - I highly doubt the results will settle much. Without a control wing, it's just not possible to definitively say what part of the patients' treatment is effective. Hopefully MSB find it in their hearts to publish the full data including patient baselines so that a proper peer reviewed journal can have a good look.
After all, there's no better way to drive physician acceptance than a full dataset, properly peer reviewed unequivocally showing efficacy and safety.
Back pain stem cell injection, page-69
-
- There are more pages in this discussion • 68 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
95.0¢ |
Change
-0.015(1.55%) |
Mkt cap ! $1.084B | |||
| Open | High | Low | Value | Volume |
| 96.5¢ | 96.5¢ | 94.5¢ | $2.433M | 2.552M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 72431 | 94.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 95.0¢ | 20225 | 5 |
View Market Depth
| Last trade - 16.10pm 27/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |